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Background & aims: Crohn’s disease (CD) is a multifactorial disease where resistance to apoptosis is one
major defect. Also, dietary fat intake has been shown to modulate disease activity. We aimed to explore
the interaction between four single nucleotide polymorphisms (SNPs) in apoptotic genes and dietary fat
intake in modulating disease activity in CD patients.
Methods: Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphism (RFLP)
techniques were used to analyze Caspase9þ93C/T, FasLigand-843C/T, Peroxisome Proliferator-Activated
Receptor gammaþ161C/T and Peroxisome Proliferator-Activated Receptor gamma Pro12Ala SNPs in 99
patients with CD and 116 healthy controls. Interactions between SNPs and fat intake in modulating
disease activity were analyzed using regression analysis.
Results: None of the polymorphisms analyzed inﬂuenced disease susceptibility and/or activity, but a high
intake of total, saturated and monounsaturated fats and a higher ratio of n-6/n-3 polyunsaturated fatty
acids(PUFA), was associated with a more active phenotype (p < 0.05). We observed that the detrimental
effect of a high intake of total and trans fat was more marked in wild type carriers of the Caspase9þ93C/T
polymorphism [O.R(95%CI) 4.64(1.27e16.89) and O.R(95%CI) 4.84(1.34e17.50)]. In the Peroxisome Pro-
liferator-Activated Receptor gamma Pro12Ala SNP, we also observed that a high intake of saturated and
monounsaturated fat was associated to a more active disease in wild type carriers [OR(95%CI) 4.21
(1.33e13.26) and 4.37(1.52e12.51)]. Finally, a high intake of n-6 PUFA was associated with a more active
disease in wild type carriers for the FasLigand-843C/T polymorphism [O.R(95%CI) 5.15(1.07e24.74)].
Conclusions: To our knowledge, this is the ﬁrst study to disclose a synergism between fat intake and SNPs
in apoptotic genes in modulating disease activity in CD patients.
 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
Crohn’s disease (CD) is a chronic inﬂammatory disease charac-
terized by a transmural and discontinuous inﬂammation of the
intestinal wall. Although the precise etiology of this disease is
unknown, most authors believe that the on-going inﬂammation
results from the interaction between genetic and environmental
factors, namely bacterial ﬂora and luminal nutrients.1,2 Among thenologia da Saúde de Lisboa,
gal. Tel.: þ351 218980400;
).
nd European Society for Clinical Nmost probably involved pathogenetic mechanisms is the imbalance
between proinﬂammatory and anti-inﬂammatory cytokines as well
as the resistance of the inﬂammatory cells to apoptotic stimuli.3,4
Both of these abnormalities are believed to contribute to perpet-
uate the inﬂammation in CD.
On the other hand, some studies have focused on the nutritional
manipulation of inﬂammation, namely through the administration of
n-3 fatty acids.5 As opposed to n-3 PUFA, and contrary to what was
formerly expected, monounsaturated acids may have a detrimental
effect,6 whereas a recent study showed that medium-chain triglyc-
erides (MCT) may exhibit an anti-inﬂammatory effect in an experi-
mental model of colitis.7 In this regard, Gassull et al., believe that the
pro or anti-inﬂammatory effect of fat dependsmore on a certain fatty
acidproﬁle thanonasingle fattyacid.6 Theexactmechanismwherebyutrition and Metabolism. All rights reserved.
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but probably relates to its ability of reducing the secretion of proin-
ﬂammatory cytokines as well as to its capacity of inducing apoptosis,
as has been shown in previous studies.8
However, the beneﬁcial or deleterious effect of the fatty acids is
not consistently observed in all studies performed. One reason for
these discrepancies could be ascribed to polymorphisms of cyto-
kine genes.9 Thus, Grimble et al.10 have shown that in a group of
healthy individuals, different genotypes for TNFa were not only
associated with different levels of TNFa production, but also with
different responses to the anti-inﬂammatory effects of ﬁsh oil.
Consistent with this hypothesis, in a previous study performed by
our group in this same population and aimed at examining the
interaction between genetic polymorphisms of pro and anti-
inﬂammatory cytokines and fat intake, we observed that different
types of fat did interact with cytokine genotype, modulating
disease activity.11
Similarly, in the present study we explored the interaction
between fat intake and four single nucleotide polymorphisms in
apoptotic genes namely Caspase-9, FasLigand and Peroxisome
Proliferator-Activated Receptor gamma in modifying both suscep-
tibility for CD as well as disease activity.
2. Materials and methods
2.1. Subjects
Ninetynineconsecutiveoutpatientswitha conﬁrmeddiagnosis of
CD, whowere coming for a routine visit to the outpatient clinic of the
two hospitals involved in the study, during the period between
September2004andNovember2007,were asked toparticipate in the
study. Demographic and clinical characteristics of study population
have been described previously.11 The diagnosis was based on
previously deﬁned criteria12 and disease activity was assessed
according to Harvey and Bradshaw Index.13 None of the patients was
on steroids at the time of the study and none was hospitalized. Only
patientswithmild tomoderate diseasewere included. The reason for
that was because we intended to analyze the association between
nutritional intake during the last year and pattern of disease activity
during this same period. Thus, itwould be amajor bias if we included
patients hospitalized for severe disease. Patients with severe active
disease (HBI>7) at the time of patient inclusion or with need of
systemic steroids were excluded (n¼ 7). One hundred and sixteen
healthy blood donors from the Instituto Português de Oncologia
Francisco Gentil S.A (IPOFG), with no previous history of inﬂamma-
tory bowel disease (IBD), were recruited as a control group for
genotyping.
2.2. Laboratory methods
Blood samples from CD patients were collected from the insti-
tutions previously mentioned and the DNA extraction was per-
formedwith phenol/chloroform extraction,14 while for controls, the
DNA extraction was made from blood samples with methodology
described in Generation Capture Card Kit e DNA Puriﬁcation/DNA
Elution (Gentra Systems, Inc., Minneapolis).
Polymerase chain reaction (PCR) and restriction fragment length
polymorphism (RFLP) techniques were used to analyze gene poly-
morphisms in the CASP9, FASLG and PPARg genes in 99 patients
with CD and 116 controls.
PCR reaction mixture included 10 buffer ([Taq buffer
þ(NH4)2SO2]), 25 mM MgCl2, 2 mM dNTPs, 6 mM forward/reverse
primer, 5U/ml TaqDNApolymerase andH2Ountil theﬁnal volumeof
20 ml. Primer sequences of the polymorphisms in study:
CASP9þ93C/T (F: 50- GGAAGAGCTGCAGGTGGAC -30/R: 50- ATGGCATGGAATCGCTTTAG -30), FASLG-843C/T (F:50- TGGGCAAACAATGAA
AATGA -30/R: 50- TCATCTCTTCCCCACACACA -30), PPARgþ161C/T (F:
50- TGAATGTGAAGCCCATTGAA -30/R: 50- TGGAAGAAGGGAAATG
TTGG -30) and PPARgPro12Ala (F: 50- ACTCTGGGAGATTCTCCT
ATTGGC -30/R: 50- CGATAGCAACGAGCTAAGCA -30).
RFLP reaction mixture included 10x appropriate reaction buffer
(New England Biolabs (NEB)), 0.08 U/mL NruI for CASP9þ93C/T, 0.17
U/mL BsrdI for FASLG-843C/T, 0.04 U/mL PmlI for PPARgþ161C/T and
0.09 U/mL HaeIII for PPARgPro12Ala (New England Biolabs (NEB)),
100 mg/ml BSA for BsrdI and PmlI enzymes and H2O until the ﬁnal
volume of 30 ml. The reaction took place for 2 h at 37 C, except for
BsrdI that digests at 65 C.
After digestion, the product was run in a 4% gel electrophoresis
and, according to the restriction proﬁle, the genotypes for each
subject were recorded.
2.3. Nutritional intake evaluation
For quantiﬁcation of the nutrients intake we used a Food
Frequency Questionnaire,15 validated for the Portuguese pop-
ulation. Participants were asked to recall their habits in the year
before the interview. Colored photographs of most food items,
showing 3 different portions sizes, as well as measuring cups and
spoons were used to facilitate quantiﬁcation of intake. Type and
quantity of food intake was then analyzed in a modiﬁed database
Food Processor software, version 7 (Esha Research, Inc, Salem, USA,
2000) including some Portuguese food items, which allow the
quantiﬁcation of different macro and micronutrients. Nutrient
values were calculated from foods and supplements.
2.4. Statistical analysis
Differences in genotype frequencies, Fisher’s exact tests and
HardyeWeinberg tests were calculated by GENEPOP (version 3.4).
Statistical analysis was performed using SPSS version 16.0 for
Windows (SPSS Inc., Chicago, EUA 2007). Data were expressed as
mean standard deviation, as number of subjects and (percentage)
or as Odds ratio (OR) and 95% conﬁdence interval (CI). Bivariate
analyses were conducted using Student’s t-test or ManneWhitney
test for continuous variables and chi-square test for categorical
ones. Multiple logistic regressions were used to study the associa-
tion between variables and disease activity.
Statistical signiﬁcance was established for p < 0.05.
Subjects were classiﬁed as homozygous for the variant if they
carried two mutated alleles, heterozygous if they carried only one
mutated allele, and ﬁnally homozygous for thewild typewhen they
had no mutant alleles. When analyzing the interaction between
genetic and nutritional variables, the median value for each
nutrient was considered.
2.5. Ethical issues
The study was approved by the Ethics and Scientiﬁc Committees
of Instituto Português de Oncologia Francisco Gentil S.A (IPOFG)
and Hospital Santa Maria. All subjects gave their informed and
written consent before entering the study.
3. Results
Clinical features and demographics of study population are
described in Table 1. Ninety nine consecutive outpatients with
a conﬁrmed diagnosis of CD (60F:39M, mean age 40.414.6 years)
had a stable body weight during the 3 months preceding the study.
According to the Harvey and Bradshaw Index (HBI), 36/99 (36.4%)
of patients had moderately active disease with an HBI 4 whereas
Table 1
Clinical features of study population.a
Clinical features Cases % (N) Controls % (N)
Age (years)b 40.4  14.6 59.7  11.8
Gender
Male 39.4 (39) 44.0 (51)
Female 60.6 (60) 56.0 (65)
Smoking habits 14.2 (30) 48.1 (102)
Years of diseaseb 11.2  8.9 e
Disease location
Ileum 29.3 (29) e
Colon 17.2 (17) e
Ileum þ Colon 53.5 (53) e
Disease phenotype
Inﬂammatory 27.3 (27) e
Penetrating 34.3 (34) e
Stricturing 38.4 (38) e
HarveyeBradshaw Index
3 64.3 (63) e
4 35.7 (36) e
Previous surgery 49.5 (49)
Current and past medication
Previous corticotherapy 80.8 (80) e
Metothrexate 6.2 (6) e
Azathioprine 78.4 (76) e
Inﬂiximab 1.0 (1) e
a N¼ 99 patients with Crohn’s disease and 116 healthy controls.
b x SD.
Table 3
Inﬂuence of polymorphisms genotype on CD activity.a
Polymorphism Inactive
disease % (N)
Active
disease % (N)
p valueb O.R (95% C.I)c
CASP9þ93 C/T
CC 34.7 (34) 18.4 (18) Ns 1
CT 26.5 (26) 16.3 (16) 1.13 (0.48e2.65)
TT 3.1 (3) 1.0 (1) 0.68 (0.06e6.87)
FASLG-843 C/T
CC 21.4 (21) 13.3 (13) Ns 1
CT 26.5 (26) 16.3 (16) 1.03 (0.40e2.63)
TT 16.3 (16) 6.1 (6) 0.65 (0.20e2.13)
PPARgPro12Ala
CC 53.9 (48) 29.2 (26) Ns 1
GC 10.1 (9) 5.6 (5) 0 (0)
GG 1.1 (1) 0 (0) 1.19 (0.35e4.09)
PPARgþ161C/T
TT 60.0 (57) 33.7 (32) Ns 1
CT 3.2 (3) 3.2 (3) 2.33 (0.41e13.13)
CC e e e
Ns, not signiﬁcant.
a High activity was deﬁned if Harvey-Bradshaw Index4.
b P values are from chi-square test.
c OR (Multiple Logistic Regression) was adjusted for age and gender.
Table 4
Inﬂuence of fat intakea on CD activity.b
Inactive
disease %(N)
Active
disease % (N)
p valuec OR (95% CI)d
Total fat
High 42.9 (27) 65.7 (23) <0.01 2.56 (1.08e6.03)
Low 57.1 (36) 34.3 (12) 1
Saturated fat
High 41.3 (26) 71.4 (25) <0.01 3.56 (1.46e8.65)
Low 58.7 (37) 28.6 (10) 1
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indices refer to at least three visits during the 1-year period.
Although controls were slightly older as compared to CD patients
(49.711.8 vs 40.414.6; p< 0.01) gender distributionwas similar
in both groups (65F:51M vs 60F:39M).
For the genetic analysis of the population we studied the
genotypic frequencies (Table 2). Except for the PPARgþ161C/T in
controls, all polymorphisms were in HardyeWeinberg equilibrium.
When examining whether any of the polymorphisms studied had
any inﬂuence in increasing the risk of developing Crohn’s disease,
we didn’t observe any signiﬁcant differences in odds ratio. The
same applies to SNPs analyses and disease activity (Table 3),
thereby suggesting that none of these SNPs alone, or in conjunction
(data not shown) predispose to a more active phenotype. Also, no
signiﬁcant association was observed between SNPs analyzed and
disease location, phenotype, age of disease onset or other charac-
teristics of disease (Data not shown). Table 4 shows the associationTable 2
Genotypic frequencies. Odd ratio for disease susceptibility.a
Polymorphism Genotypic frequencies
case/control % (N)
O.R (95% C.I)b
CASP9þ 93 C/T
CC 52.5 (52)/66.7 (76) 1
CT 43.4 (43)/31.6 (37) 1.64 (0.80e3.36) (Ns)
TT 4.0 (4)/1.8 (3) 1.03 (0.17e6.38) (Ns)
FASLG-843 C/T
CC 35.4 (35)/28.1 (33) 1
CT 42.4 (42)/55.3 (64) 0.60 (0.27e1.29) (Ns)
TT 22.2 (22)/16.7 (19) 1.02 (0.38e2.73) (Ns)
PPARgPro12Ala
CC 82.2 (74)/81.6 (95) 1
GC 16.7 (15)/16.7 (19) 1.04 (0.04e29.56) (Ns)
GG 1.1 (1)/1.8 (2) 0.96 (0.38e2.44) (Ns)
PPARgþ161C/T
TT 93.8 (90)/100 (116) e
CT 6.3 (6)/0 e
CC 0/0
Ns, not signiﬁcant.
a N ¼ 99 patients in the case group and N¼ 116 in the control group.
b OR (Multiple Logistic Regression) was adjusted for age and gender.between different types of fat intake and disease activity. We
observed that a higher intake of total, saturated and mono-
unsaturated fat was associated with a higher risk for active disease
[O.R (95% C.I) 2.56 (1.08e6.03); O.R (95% C.I) 3.56 (1.46e8.65); O.R
(95% C.I) 3.32 (1.38e7.95), respectively]. Also, patients with a higher
n-6/n-3 PUFA intake had a signiﬁcantly higher disease activity [O.R
(95% C.I) 2.30 (1.02e5.30)]. Regarding the percentage of energy
coming from dietary fat we have a mean value of 32.89%, withMonounsaturated fat
High 39.7 (25) 68.6 (24) <0.01 3.32 (1.38e7.95)
Low 60.3 (38) 31.4 (11) 1
Polyunsaturated fat
High 46 (29) 57.1 (20) Ns 1.56 (0.68e3.60)
Low 54 (34) 42.9 (15) 1
Trans fat
High 44.4 (28) 60 (21) Ns 1.86 (0.81e4.34)
Low 55.6 (35) 40 (14) 1
n-3 PUFA
High 47.6 (30) 48.6 (17) Ns 1.04 (0.45e2.38)
Low 52.4 (33) 51.4 (18) 1
n-6 PUFA
High 44.4 (28) 60 (21) Ns 1.88 (0.81e4.34)
Low 55.6 (35) 40 (14) 1
n-6/n-3 ratio
High 47.6 (30) 57.1 (20) 0.04 2.30 (1.02e5.30)
Low 52.4 (33) 42.9 (15) 1
The cut-off points were for total fat ¼ 76.7 g, saturated fat ¼ 24.7 g, mono-
unsaturated fat ¼ 33.3 g, polyunsaturated fat ¼ 11.5 g, trans fat ¼ 0.7 g, and n-3
PUFA ¼ 1.2 g; n-6 PUFA¼ 7.6 g; n-6/n-3¼ 7.3.
Ns, not signiﬁcant.
a Low or high intake refers to values above or under nutrient median intake.
b High activity was deﬁned if Harvey-Bradshaw Index4.
c P values are from chi-square test.
d OR was determined using the values above or under nutrient median intake. OR
(Multiple Logistic Regression) was adjusted for age and gender.
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value of 32.81% for patients with inactive Crohn’s disease and
33.27% for patients with a more aggressive disease, although these
differences are not statistically signiﬁcant (p¼ 0.722).
Interactions between dietary fat and polymorphisms of
apoptotic genes on disease risk are shown in Table 5. Only signiﬁ-
cant associations are displayed. To increase statistical power in
dietegene association, risk was assessed combining the heterozy-
gous and variant homozygous against the reference category of
homozygous for the more frequent allele. In respect to total fat
which per se, was already associated with a more active phenotype,
we observed that the proinﬂammatory effect of a high total fat
intake was more prominent in wild type carriers of the
CASP9þ93C/T polymorphism [O.R (95% CI) 4.64 (1.27e16.89)]. The
same applies to a high trans fat intake [O.R (95% CI) 4.84
(1.34e17.50)]. In respect to the intake of saturated and mono-
unsaturated fat, the magnitude of being associated with a more
active phenotype was similar for both wild type as well as poly-
morphic allele carriers (Table 5). In regard to the PPARgPro12Ala
SNP, we also observed that a high intake of saturated and mono-
unsaturated fat was associated to a more active disease, but in wild
type carriers only [OR (95%IC) 4.21 (1.33e13.26) and 4.37
(1.52e12.51), respectively]. Finally, a high intake of n-6 PUFA was
associated with a more active phenotype, again in wild type
carriers only for the FASLG-843C/T polymorphism [O.R (95% CI) 5.15
(1.07e24.74)].
4. Discussion
Previous studies have shown that in CD one of the basic path-
ogenic defects is resistance to apoptosis, namely of T-cells, which
certainly contributes to perpetuate inﬂammation in the intestinal
mucosa. It is also clear from previous studies that SNPs in various
genes, namely apoptotic ones, may explain not only theTable 5
Inﬂuence of the interaction between dietarya and apoptotic polymorphisms in CD
activity.b
Polymorphism
Wild type With variant
Total fat/CASP9þ93C/T
High 4.64 (1.27e16.89) 2.87 (0.79e10.52)
Low 1.0 2.23 (0.57e8.64)
Saturated fat/CASP9þ93C/T
High 6.14 (1.52e24.86) 5.14 (1.21e21.75)
Low 1.0 2.03 (0.47e8.70)
Monounsaturated fat/CASP9þ93C/T
High 3.48 (0.98e12.29) 3.78 (1.03e13.92)
Low 1.0 1.27 (0.32e5.07)
Trans fat/CASP9þ93C/T
High 4.84 (1.34e17.50) 2.27 (0.60e8.49)
Low 1.0 3.04 (0.80e11.54)
Saturated fat/PPARg Pro12Ala
High 4.21 (1.33e13.26) 2.57 (0.35e18.87)
Low 1.0 2.41 (0.45e12.89)
Monounsaturated Fat/PPARg Pro12Ala
High 4.37 (1.52e12.51) 1.66 (0.26e10.47)
Low 1.0 3.04 (0.54e17.14)
n-6 PUFA/FASLG-843C/T
High 5.15 (1.07e24.74) 2.35 (0.54e10.11)
Low 1.0 2.26 (0.53e9.69)
Analyzed by multiple logistic regression. OR, adjusted for age and gender was
determined using the values above or under nutrient median intake. The cut-off
points were for total fat ¼ 76.7 g, saturated fat ¼ 24.7 g, monounsaturated fat ¼
33.3 g, trans fat ¼ 0.7 g and n-6 PUFA ¼ 7.6 g. Combined genotype CC þ93 CASP9,
CC Pro12Ala PPARg, CC -843 FASLG and low intake was the reference category.
All tests interactions showed p > 0.05.
a Low or high intake refers to values above or under nutrient median intake.
b High activity was deﬁned if Harvey-Bradshaw Index4.heterogeneous phenotypes but also the different responses to
similar treatments. Thus, Hlavaty and colleagues16 recently
demonstrated that polymorphisms in FASLG/FAS system and CASP9
inﬂuence the response to Inﬂiximab in luminal and ﬁstulizing
Crohn’s disease.
These observations were also the rationale to explore the
associations between these same SNPs and dietary fat intake. A
number of previous experimental and human studies have shown
that dietary fat has the capacity of inﬂuencing cellular kinetics by
interfering with crucial processes such as apoptosis induction, cell
proliferation and cell differentiation. Thus, in an experimental
study using cell lines, Llor et al.8 showed that supplementationwith
ﬁsh oil and olive oil resulted in an induction of apoptosis which
could be an explanation for the putative beneﬁcial effect of these
fatty acids in the treatment of CD.
Therefore, in the present study we examined whether there was
any interaction between SNPs of apoptotic genes and dietary fat
intake in modulating disease activity in CD patients.
When analyzing the effect of fat intake per se in modulating
disease activity, we observed that a high intake of total, saturated
and monounsaturated fat was associated with more active disease
which is consistent with previous ﬁndings of Pischon et al.17, where
the results suggest that the combination of both n-6 and n-3 types
of fatty acids is associatedwith the lowest levels of inﬂammation. In
contrast, SNPs of apoptotic genes did not show any signiﬁcant
associationwith increased susceptibility to develop CD or to exhibit
a more active phenotype.
Caspase-9 (1p36) is an apoptosis-related cystein protease, which
upon binding with cytochrome c and Apaf-1 forms an apoptosome
complex and activates the executive caspases 3, 6 and 7.18 Sequential
activation of caspases plays a central role in the execution-phase of
cell apoptosis.18 To our knowledge the functionality of this poly-
morphism is not yet known. The fact that, in the present study we
observed that a high intake of total and trans fat was associated with
a more active phenotype, mainly in wild type carriers, leads us to
hypothesize that wild type carriers might exhibit more resistance to
apoptosis and, therefore there would be a synergism between two
potentially harmful factors. This is also consistent with the obser-
vations by Hlavaty et al.16 who observed that homozygotes for the
polymorphic allele had a better response to Inﬂiximab. However, this
might not be straightforward as a high intake of saturated and
monounsaturated fat, which by themselves are already associated to
amore active phenotype, have comparable effect both inwild type as
well as in polymorphic allele carriers.
PPARg (3p25) encodes amember of the peroxisome proliferator-
activated receptor (PPAR) subfamily of nuclear receptors.19 Rare
PPARg polymorphisms were found to be associated with human
Crohn’s disease.19 PPARg inhibits NFkB activity, which forms part of
a central signaling pathway that stimulates the transcription of
multiple genes that encode proinﬂammatory molecules, and diets
enriched with n-3 fatty acids are powerful PPARg activators, which
may be a plausible explanation for the anti-inﬂammatory effects of
these fatty acids.20 A common structural polymorphism in the
PPARg gene, exon 1 (CCA-GCA, producing a Pro/Ala substitution at
codon 12), has been described.20 This amino acid is located in
the PPARg domain that enhances ligand-independent activation.
The Pro/Ala change may cause a conformational change in the
protein,21 and thus patients wild type carriers of this poly-
morphism would have less inhibition of NFkB pathway and there-
fore would exhibit a more aggressive and active phenotype. Thus,
our results are consistent with the observations that a synergism
between a high intake of saturated andmonounsaturated fat exists,
thereby leading to a more active disease.
In regard to FAS receptor (FAS, CD95) and FAS ligand (FASLG,
CD95LG) these are complementary members of a particular
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Recent studies suggest that FAS-mediated apoptosis is involved in
the pathogenesis of IBD.22,23 FASLG (1q23) is a key apoptosis
inducing ligand of the TNF family of death factors.18 The FASLG-
843C/T polymorphism is located in the promoter region in
a binding site for the CAAT enhancer protein.24 A recent study
reported that carriers of the C allele of this polymorphism have
a threefold increased binding capacity to the CAAT enhancer
protein and subsequently a threefold higher expression of FASLG
that leads to an increase of apoptosis of the active cells which are
expressing FAS.16,24 Thus, wild type carriers would be more
susceptible to apoptosis and, theoretically, exhibit a less severe
phenotype. We observed that a high intake of n-6 PUFA, which is
known to promote inﬂammation, was more deleterious in wild
type carriers, as opposed towhat could be expected. The reasons for
these inconsistencies are not clear but it is worth recalling that
interactions between nutrients and genes may be extremely
complex. Furthermore, there are at least two main pathways of
apoptosis. The extrinsic pathway induced by so-called death
ligands, i.e. FAS dependent, and the intrinsic one. We may
hypothesize that n-6 PUFA inﬂuence cellular apoptosis by inter-
fering in the intrinsic pathway which does not involve the FASLG.
On the other hand, Grimble et al.10 when examining in a group of
healthy individuals the effect of a ﬁsh oil emulsion on cytokine
production, observed that this suppressive effect was maximal
when the basal production of cytokines was also maximal. Theo-
retically, the latter group would correspond to the most aggressive
phenotype and therefore a beneﬁcial effect could be harder to
obtain, as opposed to what was observed. Therefore, a number of
different hypotheses may have arisen to explain the results
observed.
To our knowledge this is the ﬁrst study examining the interac-
tion between dietary fat intake and polymorphisms of apoptotic
genes. Both are known to affect the rate of apoptosis in inﬂam-
matory cells which is known to be a major defect in the patho-
genesis of CD. However, this is an evolving ﬁeld and the long
accepted concept that saturated fat had a deleterious effect on
chronic inﬂammation, is now called into question, since a recent
experimental study showed that MCT oil, which is a saturated lipid,
might prevent a form of colitis in an animal model.7 Thus, future
studies examining the roles that these several types of dietary fat
might exert in the treatment of CD according to speciﬁc genotypes,
will be most welcome.
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